Previous close | 933.00 |
Open | 934.95 |
Bid | 934.70 x 0 |
Ask | 935.70 x 0 |
Day's range | 930.50 - 943.45 |
52-week range | 356.75 - 943.45 |
Volume | |
Avg. volume | 215,868 |
Market cap | 752.662B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 45.78 |
EPS (TTM) | N/A |
Earnings date | 06 Aug 2019 - 10 Aug 2019 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).